Adenovirus infection in the lung results in graft failure after lung transplantation  by Bridges, Nancy D. et al.
of childhood is an important determinant of outcome.1
We report here the results of systematic surveillance for
a viral pneumonitis in a predominantly pediatric lung
transplant population. We examine the impact of viral
infection of the transplanted lung on graft survival,
patient survival, and the development of obliterative
bronchiolitis (OB).
Methods
The patient population consisted of all patients undergoing
lung or heart-lung transplantation at the Children’s Hospital
of Philadelphia between December 1994 and December 1996,
with follow-up through February 28, 1997. Surveillance for
viral infection in donor tissue and recipients was performed at
the time of transplantation and at all subsequent evaluations.
Our routine schedule for surveillance transbronchial biopsy
has changed over time. Initially, surveillance transbronchial
biopsy was performed each month for the first 3 months and
then at 6 months, 1 year, and yearly thereafter. After the first
12 months’ experience in this program, we revised the sched-
A cute and chronic graft failure are major causes ofgraft loss and death after lung transplantation. The
etiology of these events is often poorly understood and
may be variously attributed to reperfusion injury, acute
cellular rejection, or “chronic rejection.” Experience
with very young lung transplant recipients has indicat-
ed that infection of the graft with the common viruses
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ule to eliminate the biopsy specimens obtained 1 and 2
months after transplantation. Throughout, we have obtained
biopsy specimens to investigate clinical findings consistent
with infection or rejection when the diagnosis could not be
made by other means or if a patient did not respond to pulsed
steroid therapy. Materials tested for the presence of virus
included lung biopsy tissue, bronchoalveolar lavage (BAL)
fluid, tracheal aspirate fluid, and (at the time of transplanta-
tion) hilar lymph nodes. Tests included examination of biopsy
tissue and BAL fluid for viral genome by polymerase chain
reaction (PCR); culture of tissue and BAL for viral isolation;
“rapid panel” testing of tracheal aspirates and BAL fluid for
virus by immunofluorescence; and histopathologic examina-
tion of tissue for cytopathologic effect, with immunohisto-
chemical staining for adenovirus and cytomegalovirus
(CMV).
All laboratory studies other than PCR were performed in
the clinical virology laboratory at the Children’s Hospital of
Philadelphia. Direct immunofluorescence testing was per-
formed for respiratory syncytial virus (RSV), influenza virus
types A and B, parainfluenza virus types 1, 2, and 3, and ade-
novirus. All PCR analyses were performed in the Phoebe
Willingham Muzzy Pediatric Molecular Cardiology Lab-
oratory at Baylor College of Medicine. The method used for
PCR identification of viruses has been previously reported.2
PCR primer pairs were designed to detect enteroviruses,
CMV (all serotypes), adenovirus (all DNA-sequenced sub-
genera); herpes simplex viruses 1 and 2; and Epstein-Barr
virus. In all cases these analyses were performed by investi-
gators blinded to the clinical picture. Serotyping of viruses
was not performed. 
Definition of clinical disease and OB. Laboratory evi-
dence of viral infection in the lung was correlated with the
presence or absence of clinical disease. A significant lung
infection was defined as the presence of at least 2 of the fol-
lowing: new densities on chest radiograph; decreased arterial
oxygen saturation, compared with the patient’s baseline level;
or fever, cough, dyspnea, or new abnormal auscultatory find-
ings. In the context of these clinical findings, the date of diag-
nosis of viral pneumonitis was defined as the date on which
the specimen in which virus was ultimately identified was
obtained. OB was diagnosed according to the criteria of the
working formulation group of the International Society for
Heart and Lung Transplantation3: that is, the presence of
eosinophilic fibrous scarring in the walls of the small con-
ducting airways, with partial or complete obliteration of the
lumen. Because only 5 of the 16 patients in this study were
mature enough to reliably perform pulmonary function test-
ing, the clinical diagnosis of bronchiolitis obliterans syn-
drome was not used. However, for each of those 5 patients,
the results of pulmonary function testing correlated with the
presence or absence of histologically defined OB. Graft sur-
vival was defined as the interval between implantation and
explantation in the case of patients receiving a second trans-
plant, or from implantation to death in patients who died.
Statistical methods. Variables examined for a statistically
significant association with graft survival, patient survival,
and OB included adenovirus infection in the lung, other viral
infection in the lung (CMV, RSV, influenza B virus, or rhi-
novirus), age at transplantation, sex, and number of episodes
of acute rejection graded A3 or higher. Univariate analysis
was performed with the use of the c 2 test for discrete vari-
ables and regression for continuous variables. Among the
variables examined, only adenovirus infection was signifi-
cantly associated with graft loss, patient survival, or OB.
These outcomes were examined by means of the Cox pro-
portional hazards model, with adenovirus infection entered as
a time-dependent variable. Statistical analysis was carried out
with the use of Stata software (Stata Corporation, College
Station, Tex).
Results
Patient characteristics are shown in Table I. The
group comprised 16 patients (8 female) who had 19
thoracic organ transplants: 11 primary lung transplants,
4 primary heart-lung transplants, and 4 second lung
transplants. Patients’ ages ranged from 3 months to 41
years (median 4.6 years). Among the 15 patients under-
going primary transplantation, there was 1 early death
(patient 16) caused by adenovirus pneumonia, for an
operative survival of 93%. Among the 4 patients under-
going a second transplant operation, there was 1 early
death (patient 6) caused by Aspergillus cerebritis, for
an operative survival of 75%.
Results of viral surveillance. In all, 59 specimens
(lung tissue, BAL, or tracheal aspirate) were examined
by PCR; 84 specimens (lung tissue, BAL, or tracheal
aspirate) were cultured for viral isolation; 61 speci-
mens (BAL or tracheal aspirate) were studied by direct
immunofluorescence, and 59 specimens (lung tissue)
were subjected to histologic examination. Of the 59
biopsy specimens, 28 (47%) were obtained within the
first 3 months of transplantation. Virus was identified in
the transplanted lung on 29 occasions, for a frequency of
0.13 events per patient-month of follow-up. In 2
instances, 2 viruses were identified concurrently at the
time of a clinical illness: in 1 case (patient 7), CMV
and adenovirus were identified concurrently, and in the
other (patient 14), parainfluenza and RSV were identi-
fied concurrently. Both of these cases are discussed
later. Adenovirus was the virus most frequently identi-
fied and most commonly associated with severe illness
in this group of patients and thus became the primary
focus of our analysis.
Next in frequency of identification after adenovirus
was RSV, which was found 9 times in 8 patients. One
patient was identified as having RSV at the time of
transplantation, with no clinical illness evident either
before or after transplantation. In 7 instances, RSV was
associated with a mild respiratory illness characterized
by small decreases in arterial oxygen saturation, mild
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wheezing on auscultation, little or no change in
roentgenographic appearance of the lungs, and in 2
instances, gastroenteritis. In 3 of these cases, patients
were hospitalized for intravenous hydration, for sup-
plemental oxygen via nasal cannula, or for both treat-
ments. All of these patients recovered without seque-
lae. In 1 patient (patient 7), RSV was identified in a
tracheal aspirate specimen obtained at the time of over-
whelming, fatal Pseudomonas sepsis; the significance
of this finding is unclear.
Both cases of CMV were associated with significant
respiratory disease. In 1 case, CMV was identified con-
currently with adenovirus, at a time when the patient
was receiving ganciclovir; that patient had fulminant
respiratory failure and underwent a second lung trans-
plantation. In the other, the patient’s pneumonitis was
treated with intravenous ganciclovir, and she recov-
ered. However, OB subsequently developed and she
underwent a second lung transplantation.
Both cases of parainfluenza were also associated
with significant respiratory disease, characterized by
decreased arterial oxygen saturations, increased work
of breathing, wheezing on auscultation, and diffuse
interstitial densities on chest radiograph. In 1 of these 2
patients, RSV was identified concurrently with parain-
fluenza. Both patients were hospitalized and treated
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Table I. Patient characteristics
Age at 
Indication for transplantation Transplant 
Patient transplantation (y) procedure Outcome
1 PHN with CHD 19.8 Primary bilateral lung Second transplant for OB
with cardiac repair
2 PHN with CHD 0.25 Primary bilateral lung Alive and well, histologic diagnosis 
with cardiac repair of OB
3 Pulmonary vein stenosis 2.3 Primary bilateral lung Alive and well
with cardiac repair
4 PHN with CHD 12.8 Primary bilateral lung Alive and well, histologic diagnosis 
with cardiac repair of OB
5 OB due to GVHD after bone 5.8 Primary bilateral lung Alive and well
marrow transplantation
6 (first graft) Bronchopulmonary dysplasia 1.9 Bilateral lung Second transplant for graft failure
6 (second graft) OB after adenovirus pneumonia 2.6 Bilateral lung Died 9 days after second transplant,
from cerebral Aspergillus infection
7 (first graft) Primary pulmonary hypertension 2.1 Bilateral lung Second transplant for graft failure
with cardiac repair
7 (second graft) Fulminant graft failure after 2.2 Repeat bilateral lung Died 15 mo after second transplant,
adenovirus pneumonia from Pseudomonas sepsis
8 Cystic fibrosis 15 Primary bilateral lung Died of OB after refusing a second 
transplant 
9 OB after heart and lung 4.6 Repeat bilateral lung Died 12 mo after second transplant,
transplantation from respiratory failure after 
adenovirus pneumonia
10 (first graft) PHN with CHD 7 Primary heart and lung Second transplant for graft failure; 
see below
10 (second graft) Acute graft failure after 7.1 Bilateral lung Died 11 mo after second transplant,
adenovirus pneumonia and after a second adenovirus infection
aspiration
11 Congenital pulmonary vein stenosis 0.23 Primary bilateral lung Alive and well
with cardiac repair
12 PHN with CHD 41.5 Primary heart and lung Alive and well
13 PHN with CHD 7.1 Primary heart and lung Alive and well, with histologic 
diagnosis of OB
14 Congenital chylothorax 0.7 Primary bilateral lung Alive and well
15 PHN with CHD 24.8 Primary heart and lung Alive and well
16 PHN after repair of congenital 0.3 Single lung Died of respiratory failure from 
cystic adenomatoid malformation adenovirus pneumonia, while 
waiting for a second transplant
PHN, Pulmonary hypertension; CHD, congenital heart disease; OB, obliterative bronchiolitis; GVHD, graft-versus-host disease.
*Patient 9 underwent her first transplant procedure (heart and lung transplantation for pulmonary hypertension in association with congenital heart disease) at another
institution.
with intravenous hydration and supplemental oxygen
by nasal cannula; both recovered. OB later developed
in 1 patient after an episode of adenovirus pneumonia.
Both cases of rhinovirus were associated with mild
upper respiratory tract illnesses. Identification of
Epstein-Barr virus, herpes simplex virus, and influenza
B was not associated with clinical respiratory illness.
Identification of adenovirus in the transplanted
lung. In 10 grafts, there was no evidence of adenovirus
infection. Of these, 2 are in patients who had aden-
ovirus identified in a prior graft. Thus 8 of 16 patients
have been free of adenovirus in the transplanted lung.
Among these 8 patients, 6 have no evidence of OB, 1 is
free of symptoms but has a histologic diagnosis of OB,
and 1 has undergone a second transplant operation
because of OB in the first graft.
Adenovirus was identified in 9 grafts over a period of
almost 18 months (Table II). In 2 instances, 2 patients
were infected within a 1-week period. In the first
instance, 1 patient acquired the infection from the
donor, and the other acquired it in the community. In
the second instance, 2 infections were identified within
a 5-day period in patients in the intensive care unit. The
other 5 infections were separated by time intervals of 1
to 6 months. The remaining 8 patients (9 grafts) all had
evidence of adenovirus infection. One of the grafts was
infected with adenovirus on 2 separate occasions, 11
months apart, for a total of 10 infectious episodes in 9
grafts in 8 patients. In patients identified as having ade-
novirus pneumonia, routine triple-drug immunosup-
pression was maintained, with tacrolimus or cyclo-
sporine (INN: ciclosporin) levels maintained at the
low end of the therapeutic range (6-10 ng/mL or 150-
200 ng/m L, respectively).
In 2 patients, adenovirus was identified in the trans-
planted lung by PCR only, without clinical pneumoni-
tis or confirmation by other laboratory studies. Both of
these patients subsequently had both histologic and
clinical evidence of OB; one died after refusing a sec-
ond lung transplant operation, and the other has been
listed for a second lung transplantation. For the pur-
poses of statistical analysis, these patients were not
considered to have had adenovirus infection in the
lung.
In 2 patients (3 grafts), adenovirus was identified in
the lung by PCR at the time of a clinical pneumonitis,
without other laboratory confirmation. No other organ-
isms were identified to account for the clinical find-
ings. In 1 of these patients, fulminant graft failure
developed, and the patient underwent a successful sec-
ond transplant operation; she died 11 months later of
respiratory failure, with adenovirus identified only by
PCR in the second graft. The other patient had pro-
gressive graft failure starting at the time of the aden-
ovirus infection; she died of respiratory failure.
Finally, in 5 patients (5 grafts), adenovirus was iden-
tified at the time of clinical pneumonitis by PCR as
well as at least 1 other laboratory method. In 2 of these
5, both of whom had early, rapidly progressive infec-
tions leading to graft failure, adenovirus was also iden-
tified by PCR in the donor lung before implantation.
One of these patients had successful retransplantation
after a period of support with extracorporeal membrane
oxygenation, and the other died while waiting for a sec-
ond donor organ. Chronic graft failure with histologic
evidence of OB and graft vasculopathy developed in a
third patient, who had a second transplant operation.
Acute severe respiratory failure developed in the fourth
patient in this group; although he recovered and is clin-
ically well, he has a histologic diagnosis of OB 1 year
later. The last patient in this group had a less severe
clinical illness at the time that adenovirus was identi-
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Table II. Detection of adenovirus in the transplanted lung
Interval from 
transplantation to 
detection of adenovirus Laboratory Clinical 
Patient (d) evidence Histology pneumonitis?
4 458 PCR Lymphocytic bronchitis No
6 232 PCR, rapid, culture Acute pneumonia, viral cytopathic effect Yes
7 1 PCR, culture Diffuse necrotizing bronchitis, positive tissue Yes
stain for adenovirus
9 (first infection) 16 PCR, rapid, culture Nonspecific mild acute inflammatory infiltrate Yes
9 (second infection) 298 PCR Diffuse alveolar damage; normal airways Yes
10 (first graft) 46 PCR Organizing pneumonia and OB Yes
10 (second graft) 290 PCR Organizing pneumonia and OB Yes
13 37 PCR, rapid, culture Organizing pneumonia and OB Yes
16 18 PCR, rapid, culture Diffuse alveolar damage, acute bronchitis, OB Yes
PCR, Polymerase chain reaction; rapid, rapid panel testing by immunofluorescence; OB, obliterative bronchiolitis.
fied in her lung; she recovered from that episode but
died 12 months later of respiratory failure after a sec-
ond adenovirus lung infection.
Impact of adenovirus on graft and patient survival.
Among the 8 patients in whom adenovirus was identified
in the transplanted lung, only 2 were still alive at the end
of the follow-up period. Both have histologic evidence of
OB. Death from respiratory failure occurred in 4 patients
3 weeks, 10 months, 12 months, and 15 months after
transplantation, respectively. The other 2 patients died of
unrelated extrapulmonary infections after a second lung
transplantation (Aspergillus cerebritis in 1, Pseudomonas
sepsis in the other), with good graft function.
Among the 19 grafts implanted during the study peri-
od, 3 failed abruptly in the immediate postoperative
period. Adenovirus was identified in all. Two of these
patients underwent a second lung transplantation; the
third died before organs became available. In all, 3
patients underwent a second lung transplantation for
respiratory failure after adenovirus infection (2 early
and 1 late). In only 1 of these 3 patients was adenovirus
identified in the second graft, and that patient died of
chronic progressive respiratory failure. The other 2
died of unrelated infections, with good graft function.
In a Cox proportional hazards analysis in which ade-
novirus infection was entered as a time-dependent vari-
able, adenovirus infection was significantly associated
with graft loss (P = .002, coefficient 2.67, 95% CI 1.0-
4.3), patient death (P < .001, coefficient 37.7, 95% CI
36.9-38.5) and with the histologic diagnosis of OB (P <
.0001, coefficient 36.2-37.5, 95% CI 36.2-37.5).
Survival with and without adenovirus is depicted in Fig
1; survival without adenovirus infection is taken as the
interval from transplantation to last follow-up or to the
date of identification of adenovirus infection, at which
point patients are censored; survival after adenovirus
infection is taken as the interval between identification
of adenovirus infection and last follow-up or death. The
difference in survival is significant (P = .001 by the
Wilcoxon-Gehan test). None of the other variables
examined (age, sex, number of episodes of acute rejec-
tion, and identification of other viruses in the trans-
planted lung) were significantly associated with graft
loss, death, or OB in this group.
Discussion
Adenovirus is a ubiquitous virus of childhood,
accounting for about 5% of acute upper respiratory
tract illnesses and about 10% of pneumonias in chil-
dren under age 5 years; asymptomatic carriage of the
virus is common, and the transmission rate is high.4,5
Adenovirus is also known to be an important pathogen
in immunocompromised hosts, including newborn
infants6,7 and recipients of bone marrow, kidney, and
liver transplants, infecting both the transplanted and
other organs.8-10 Ohori and associates11 reported on 4
patients (3 of them children) with fulminant adenovirus
pneumonia after lung transplantation, all of whom
died. We1 have previously reported the high incidence
of adenovirus infection in a series of very young chil-
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Fig 1. Actuarial survival after lung transplantation. Survival without adenovirus infection, shown in the upper
curve, is taken as the interval from transplantation to last follow-up or to the date of identification of adenovirus
infection, at which point patients were censored; survival after adenovirus infection is taken as the interval
between identification of adenovirus infection and last follow-up or death. The difference in survival is signifi-
cant (P = .001 by Wilcoxon-Gehan test).
dren undergoing lung transplantation. In the current
report, adenovirus is again shown to be an agent of
acute fulminant graft failure. To our knowledge, this is
the first report to demonstrate a significant association
between adenovirus in the transplanted lung and histo-
logically proven OB.
Although the cause of OB remains elusive, there is
some consensus that it is a multifactorial, immunologi-
cally mediated process.12,13 Several investigators have
demonstrated a relationship between OB and acute cel-
lular rejection, and this relationship appears to be poten-
tiated by infection, most notably CMV.14-18 Although
neither rejection nor CMV emerged as an important pre-
dictor of early or late graft failure in the current analy-
sis, both patients who had CMV pneumonitis eventually
had OB and graft failure leading to a second lung trans-
plantation. Thus the lack of statistical significance for
these variables is likely due to the small number of
patients in this study. It is also possible that these factors
are overshadowed by other features (specifically, sus-
ceptibility to viral pneumonitis) related to our patients’
young age; previous authors have noted that infection
with respiratory viruses is a more serious problem in
younger transplant recipients.19
Adenovirus, whether wild type or replication deficient,
elicits a strong immune response in the lung.20 Thus the
relationship demonstrated in this study between aden-
ovirus and OB in lung transplant recipients is plausible.
Adenovirus pneumonia is a known (though rare) cause
of OB in immunocompetent children21 and has been
demonstrated to cause OB in immunocompetent animal
models.22 Adenovirus can be associated with chronic or
persistent infection and, in either case, is known to be
associated with chronic airway obstruction and deterio-
ration of lung function.23,24 Finally, adenovirus is a
mediator of apoptosis,25,26 a process that may have a role
in the pathogenesis of OB.27
The prevalence of adenovirus in young patients and
the ease with which it is transmitted, particularly as a
nosocomial infection,28,29 make this a troubling find-
ing. Two of the patients in this series who had early
graft loss as a result of adenovirus pneumonia received
the virus from their donors. Mild viral symptoms in an
infant or toddler are so common that this history might
be overlooked in the evaluation of a donor. Further-
more, viral respiratory infections of all sorts are com-
mon in healthy children, as well as in those who receive
transplants. In the early stages of infection, those that
are generally benign in transplant recipients, such as
RSV and rhinovirus, are clinically indistinguishable
from those with more serious consequences, such as
adenovirus and parainfluenza. PCR methodology has
been demonstrated to be a reliable and clinically useful
tool in the specific diagnosis of viral infections in heart
transplant recipients.30 However, given the time con-
straints that exist at the time of cadaveric donor lung
transplantation, reliable confirmation of the presence or
absence of adenovirus in a potential donor before trans-
plantation is usually not feasible.
Summary and conclusions
Systematic surveillance for viral infection in the lung
in a predominantly pediatric group of lung transplant
recipients reveals a significant association between
adenovirus infection and graft loss, OB, and death. The
prevalence of adenovirus in young children makes this
an important finding. Personnel in inpatient units car-
ing for lung transplant recipients must be vigilant in
isolation precautions to prevent the nosocomial spread
of this common virus, and families must be counseled
to prevent contact between transplant recipients and
individuals with even mild respiratory infections or
conjunctivitis. Identification of adenovirus pneumoni-
tis is an indication for relisting in our program, and this
approach has been successful when organs can be
obtained in time; early reinfection has not occurred.
The ability to make a rapid and reliable assessment for
the presence or absence of adenovirus in donors and
recipients would improve our ability to care for these
patients and could potentially have an important effect
on their outcome.
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